New -Lactamase Inhibitors Nacubactam and Zidebactam Improve the in Vitro Activity of -Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates
Date:
08/23/2019
Topics:
Citation:
Kaushik A, Ammerman NC, Parrish NM, Nuermberger EL. New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates. Antimicrob Agents Chemother. 2019 Aug 23;63(9):e00733-19. doi: 10.1128/AAC.00733-19. PMID: 31209013; PMCID: PMC6709484.
Abstract
The new diazabicyclooctane-based β-lactamase inhibitors avibactam and relebactam improve the in vitro activity of β-lactam antibiotics against bacteria of the Mycobacterium abscessus complex (MABC). Here, we evaluated the in vitro activities of two newer diazabicyclooctane-based β-lactamase inhibitors in clinical development, nacubactam and zidebactam, with β-lactams against clinical isolates of MABC. Both inhibitors lowered the MICs of their partner β-lactams, meropenem (8-fold) and cefepime (2-fold), respectively, and those of other β-lactams, similar to prior results with avibactam and relebactam.